THERAPEUTICS

VACCINES

CRM-197

Background

• CRM-197 is a genetically detoxified Diphtheria toxin, which is a widely used carrier protein for protein-polysaccharide conjugate vaccines.
• CRM-197 is widely used as carrier protein in the conjugate vaccines against Streptococcus pneumoniae, Haemophilus influenzae b, Neisseria meningitides, etc. by the leading vaccine manufacturers.

Salient features of CRM-197 from Lorven Biologics

• Conjugation ready recombinant carrier protein
• Structurally and functionally similar to native CRM-197
• 96.0% pure, available at an economical price
• Expressed in our proprietary bioengineered Bacillus subtilis expression system
• Saving the process costs significantly through direct secretion of active CRM197 into the growth media
• Endotoxin free secretion system
• High yields (500 mg to 1.5 gram/L/hr) lead to the decrease in the production cost.

Strategy for rCRM-197 Strain Development at Lorven:

Product quality

• Biologically identical to native CRM197
• 100% native conformation
• High immunogenicity as a carrier with vaccine
• Free from animal-derived components

Safety

Bacillus subtilis: Genetically highly amenable host organism with BSL-1 maintenance.

Intellectual Property

International patent is held by Lorven Biologics Pvt. Ltd. Title: Nucleic acid encoding CRM197 and process for improved expression thereof (WO2019043593A1)